ANL (Adlai Nortye) Moat Score: 4/10 (As of Jul. 02, 2026)


What is Adlai Nortye Moat Score?

Adlai Nortye ANL -10.38% Moat Score is 4 as of Jul. 02, 2026. The stock has 7 warning signs investors should review. Among 1,400 Biotechnology companies, Adlai Nortye ranks better than 88.79% on this metric.

Adlai Nortye has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Adlai Nortye has Narrow Moat: Adlai Nortye has a discernible moat due to its focus on innovative cancer therapies and some valuable patents. However, it lacks strong brand strength and significant market share, limiting its moat to a narrow category.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Adlai Nortye might have Narrow Moat - Discernible but modest moat.

Adlai Nortye  (NAS:ANL) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Adlai Nortye Moat Score Related Terms

ANL vs OMER, PRME, DNA: Moat Score Comparison

For the Biotechnology subindustry, Adlai Nortye's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Moat Score distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Adlai Nortye (ANL) has a Moat Score of 4 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Adlai Nortye ranks #157 out of 1400 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Adlai Nortye's Moat Score too high?
Adlai Nortye's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Adlai Nortye's value of 4 is 100% above this industry median. Based on the distribution chart, Adlai Nortye ranks #157 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Adlai Nortye's Moat Score compare to OMER and PRME?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #157 out of 1400 companies for Moat Score. This places Adlai Nortye in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Adlai Nortye's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adlai Nortye's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Moat Score is 4 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.